ADGRE2/EMR2 recombinant proteins and antibodies

Adhesion G protein-coupled receptor E2 (ADGRE2), also known as EMR2, is a G protein-coupled receptor (GPCR) widely expressed in various immune cells, including eosinophils, monocytes, and dendritic cells. ADGRE2 plays a critical role in regulating immune responses, cell migration, and inflammation through its interaction with ligands. As a key modulator of the immune system, ADGRE2 contributes to immune tolerance, allergic responses, and tissue repair. Additionally, ADGRE2 is implicated in the pathogenesis of certain cancers and autoimmune diseases.

ADGRE2 plays a vital role in several immune-mediated diseases, particularly in allergic and inflammatory conditions. For example, ADGRE2 is involved in asthma, allergic rhinitis, and rheumatoid arthritis, where it regulates eosinophil activity and migration, thereby influencing the intensity and duration of immune responses. Moreover, ADGRE2 has been shown to participate in immune evasion and tumor microenvironment formation, making it a potential target for cancer immunotherapy.

Currently, drug development targeting ADGRE2 is focused on small molecule inhibitors and antibody therapies. Small molecule inhibitors work by inhibiting ADGRE2 activity, reducing excessive immune cell activation, and alleviating allergic reactions, improving immune tolerance, and suppressing tumor growth. Furthermore, monoclonal antibodies targeting ADGRE2 are under development, aiming to specifically bind to ADGRE2 and block its interaction with ligands, thereby modulating immune responses. With further understanding of ADGRE2’s function, ADGRE2-targeted therapies are expected to offer new treatment options for allergic conditions, immune diseases, and cancer in the next few years.

To assist in the development of ADGRE2 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for ADGRE2 targets. Products include active ADGRE2 recombinant proteins, full-length ADGRE2 proteins, ADGRE2 reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of ADGRE2 biotherapy, DIMA BIOTECH has also prepared a ADGRE2 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple ADGRE2 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.